Salubris(SZ:002294) Xin Lang Cai Jing·2025-09-19 06:29Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is located in Futian District, Shenzhen, Guangdong Province, and was established on November 3, 1998. The company was listed on September 10, 2009. Its main business involves the research, production, and sales of pharmaceuticals and medical devices [1]. - The revenue composition of the company is as follows: formulations account for 81.69%, medical devices 8.54%, raw materials 7.17%, and others 2.59% [1]. Stock Performance - On September 19, Xinlitai's stock fell by 5.14%, closing at 51.70 CNY per share, with a trading volume of 301 million CNY and a turnover rate of 0.51%. The total market capitalization is 57.636 billion CNY [1]. Fund Holdings - According to data from the top ten holdings of funds, one fund under Shangyin Fund has a significant position in Xinlitai. The Shangyin Healthcare Mixed A Fund (011288) held 236,300 shares in the second quarter, unchanged from the previous period, representing 5.18% of the fund's net value, making it the third-largest holding [2]. - The Shangyin Healthcare Mixed A Fund was established on March 30, 2021, with a current scale of 107 million CNY. Year-to-date returns are 54.57%, ranking 741 out of 8172 in its category, while the one-year return is 68.95%, ranking 1757 out of 7980. Since inception, the fund has incurred a loss of 12.82% [2]. Fund Manager Information - The fund manager of Shangyin Healthcare Mixed A Fund is Yang Jiannan, who has been in the position for 3 years and 208 days. The total asset size of the fund is 216 million CNY, with the best return during his tenure being 13.72% and the worst return being 12.51% [3].